Len Kanavy - 12 Dec 2025 Form 4 Insider Report for Merus N.V. (MRUS)

Reporting relationship: Director
Issuer ticker: MRUS
Reported as of: 12 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Dec 2025, 19:04:23 UTC
Prior SEC filing: 27 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter Silverman as attorney-in-fact

Filing notes and source

Key filing fact

Len Kanavy filed Form 4 for Merus N.V. (MRUS) on 12 Dec 2025.

Key facts

This page summarizes Len Kanavy's Form 4 filing for Merus N.V. (MRUS).
9 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 12 Dec 2025, 19:04.

Change

Previous filing in this sequence was filed on 27 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789990 Primary reporting owner

Kanavy Len

Relationship: Director
Address: C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, NETHERLANDS
Signature: /s/ Peter Silverman as attorney-in-fact
Signature date: 12 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,193
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 13,193
Exercise price: $41.60
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -8,844
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 8,844
Exercise price: $48.73
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -14,414
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 14,414
Exercise price: $23.29
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -16,604
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 16,604
Exercise price: $18.56
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -6,120
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 6,120
Exercise price: $21.15
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -8,631
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 8,631
Exercise price: $16.09
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -14,149
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 14,149
Exercise price: $20.80
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -7,669
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 7,669
Exercise price: $14.83
Footnotes: F1, F2

MRUS transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -8,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 8,500
Exercise price: $13.35
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Len Kanavy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

Footnote F2

This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.